American Regent v. Cipla: Selenious Acid Injection Patent Case Consolidated
American Regent, Inc. brought a patent infringement action against Cipla Limited in the District of New Jersey, asserting US11998565B2 covering selenious acid injection formulations used in parenteral nutrition. The case was consolidated with related proceedings within 128 days of filing, suggesting parallel ANDA litigation targeting the same patent family.
Selenium IV Formulation Patent Draws Pharma Consolidation in New Jersey
On July 16, 2024, American Regent, Inc. filed a patent infringement complaint against Cipla Limited in the U.S. District Court for the District of New Jersey, asserting U.S. Patent No. 11,998,565 B2. The patent covers selenious acid injection formulations — specifically intravenous selenium products supplied at 60 mcg/mL (10 mL vial) and 6 mcg/mL (2 mL vial) concentrations — used in parenteral nutrition protocols.
The case closed on November 21, 2024, not through a merits ruling or settlement, but through consolidation into a broader coordinated action. The court’s consolidation order directed that all future filings in the consolidated action use a unified caption, a procedural mechanism typically deployed when multiple ANDA filers assert similar defenses against the same reference-listed drug patent, allowing the court to manage discovery and claim construction efficiently across defendants.
The 128-day timeline from filing to consolidation is consistent with an early-stage procedural alignment rather than any substantive merits development. The public record does not disclose which other defendants or case numbers were joined in the consolidated action, nor whether Cipla has filed an ANDA or a Paragraph IV certification. The underlying validity and infringement disputes relating to US11998565B2 are presumed to remain live in the consolidated proceeding.
Filing to Case Consolidated in 128 days
128 days to consolidation — faster than the median NJ pharma patent case
Case consolidated: what the procedural merger means for both parties
Consolidation ends this docket — litigation continues elsewhere
Case consolidation under Fed. R. Civ. P. 42(a) merges related actions sharing common questions of law or fact into a single proceeding. This case (2:24-cv-07796) was absorbed into a consolidated action, meaning the docket closes but the substantive claims — infringement of US11998565B2 — live on under the unified caption. No merits have been adjudicated.
Procedural — no merits rulingAmerican Regent retains full infringement claims
Consolidation does not extinguish American Regent’s infringement allegations. The patent holder continues to assert US11998565B2 in the unified action, likely alongside claims against other ANDA filers targeting the same selenious acid reference-listed drug. Consolidation may benefit the patentee by producing a single, binding claim construction ruling applicable to all defendants simultaneously.
Claims preservedCipla faces coordinated multi-defendant proceedings
Cipla is now part of a consolidated action that likely includes other generic challengers. This arrangement can impose cost efficiencies but also limits each defendant’s ability to control the litigation pace independently. Cipla’s invalidity and non-infringement arguments will be heard alongside those of co-defendants, which may affect settlement leverage and claim construction strategy.
Litigation continuesSelenium IV patent creates multi-front generic entry barrier
US11998565B2 covers a clinically essential parenteral nutrition micronutrient. Consolidation of multiple ANDA challenges against this patent signals that several generic manufacturers are racing for market entry. The consolidated proceeding will produce authoritative rulings on validity and infringement that affect all generic filers simultaneously — raising the stakes of any single adverse ruling for the entire generic pipeline.
ANDA race — high sector stakesFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | American Regent, Inc. | Company | Pharmaceutical manufacturer — holder of US11998565B2 for selenious acid injectionSearch in Eureka ↗ |
| Defendant | Cipla Limited | Individual | Cipla Limited — global generic pharmaceutical manufacturer, India-headquarteredSearch in Eureka ↗ |
| Co-Defendant | CIPLA Limited | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christine A. Gaddis | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Dennies Varughese | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Sterne Kessler Goldstein & Fox | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Defendant counsel | Rebekah R. Conroy | Attorney | Counsel for Cipla LimitedSearch in Eureka ↗ |
| Defendant law firm | Stone Conroy LLC | Law Firm | Representing Cipla LimitedSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order — directing all filings to use a unified caption going forward — is a purely procedural disposition. It confirms that this docket has been subsumed into a consolidated action but makes no ruling on infringement, validity, or claim scope. The phrasing ‘WHEREFORE’ is standard order language and carries no substantive significance. Both parties’ rights and obligations under US11998565B2 remain entirely unresolved pending proceedings in the consolidated action.
US11998565B2 — Selenious Acid Injection USP Formulations
U.S. Patent No. 11,998,565 B2, issuing from application US18/124391, covers selenious acid injection formulations used to deliver selenium intravenously in parenteral nutrition settings. The asserted products — a 60 mcg/mL (10 mL) and a 6 mcg/mL (2 mL) formulation — are clinical-use micronutrient solutions. The patent’s relatively recent issuance suggests it protects a specific formulation, concentration, or manufacturing innovation rather than the underlying compound, which is long-established.
For the parenteral nutrition sector, control of a key micronutrient injection patent creates a durable barrier to generic entry even for well-established active ingredients. American Regent’s assertion of US11998565B2 against at least one major generic manufacturer signals confidence in the patent’s enforceability and scope. Competitors developing ANDA products in the selenium IV space should treat this patent as a primary FTO target and closely monitor claim construction developments in the consolidated New Jersey proceeding.
Should you run an FTO analysis against US11998565B2?
Any company developing, manufacturing, or commercialising selenious acid injection products — particularly at the concentration ranges of 6 mcg/mL or 60 mcg/mL — should treat US11998565B2 as a live FTO risk. The ongoing consolidated litigation in New Jersey means claim construction is unresolved, making current product designs vulnerable to an adverse Markman ruling. R&D teams reformulating selenium IV products should assess whether proposed specifications fall within or outside the patent’s claim scope before committing to ANDA filing.
PatSnap Eureka’s FTO Search Agent can map the full claim landscape of US11998565B2 against your product specifications, surface relevant prosecution history disclaimers, and identify prior art that may support design-around or invalidity arguments. Eureka also tracks the consolidated NJ docket in real time, alerting your team to scheduling orders, Markman outcomes, and any narrowing constructions that change the FTO picture — enabling faster, lower-risk go/no-go decisions for your ANDA programme.
Run a freedom-to-operate analysis on US11998565B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA Patent Cases: Parenteral Nutrition & Injectable Micronutrients
Related infringement actions in the NJ District Court targeting injectable micronutrient and parenteral nutrition ANDA products with consolidated multi-defendant proceedings.
What this case signals for the parenteral nutrition IP landscape
A rapidly consolidated ANDA docket around a selenious acid patent points to intensifying generic competition in the IV micronutrient space.
Consolidation signals multiple ANDA filers targeting US11998565B2
When a district court consolidates pharmaceutical patent cases within months of filing, it typically indicates that two or more generic manufacturers have filed substantially similar Paragraph IV certifications against the same reference-listed drug. Companies tracking generic entry risk for selenious acid injection products should monitor the consolidated docket for scheduling orders and claim construction briefing.
Parenteral selenium is an underwatch space for ANDA patent litigation
Selenious acid injection is a critical-use parenteral micronutrient with limited branded competition. Litigation asserting a recently issued patent (US11998565B2) against generic filers suggests American Regent is actively protecting a reformulated or newly patented product position — a pattern seen across other injectable micronutrient categories like iron and zinc.
American v Cipla — key questions answered
American Regent filed a patent infringement action against Cipla in the District of New Jersey on July 16, 2024, asserting US11998565B2 covering selenious acid injection formulations. The case was closed on November 21, 2024 — not on the merits — but through consolidation into a broader coordinated action. Infringement and validity of the patent remain unresolved in the consolidated proceeding.
US11998565B2, issuing from application US18/124391, covers selenious acid injection USP formulations used to deliver selenium intravenously in parenteral nutrition. The asserted products include a 60 mcg/mL (10 mL) and a 6 mcg/mL (2 mL) formulation. Its commercial significance lies in blocking generic ANDA entry into a clinically essential IV micronutrient market with limited branded competition.
Consolidation under Fed. R. Civ. P. 42(a) merges cases sharing common questions of law or fact. When a patent case is consolidated, the original docket closes and all proceedings — including discovery, claim construction, and trial — continue under a unified caption. No merits ruling is made at the point of consolidation; all infringement and validity claims remain live.
The public record for case 2:24-cv-07796 indicates consolidation into a broader action, suggesting at least one other related case exists in the District of New Jersey. The specific consolidated case number and co-defendants are not disclosed in the available record. Monitoring the NJ District Court PACER docket under the consolidated caption would reveal the full defendant roster.
Any manufacturer targeting the selenious acid injection market — particularly at 6 mcg/mL or 60 mcg/mL concentrations — should conduct a freedom-to-operate analysis against US11998565B2 before finalising product specifications or submitting an ANDA. Claim construction in the consolidated NJ proceeding remains pending, meaning the enforceable scope is still being defined. Prosecution history review may reveal claim limitations that support design-around or non-infringement arguments.
PatSnap Eureka searches patents and litigation data to answer instantly.